Emerging peptide · Preclinical & theoretical

Kisspeptin (KP-54)

Endogenous neuroendocrine peptide regulating reproductive hormone release — emerging as a candidate for fertility, sexual response, and mood applications.

Phase 1/2

Investigational compounds — read carefully

This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.

Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.

At a glance

A regulator at the top of the reproductive endocrine axis. Imperial College London's Dhillo group has driven much of the early-phase human work, with applications spanning fertility, sexual function, and emotional response.

Class
Endogenous KISS1-derived neuropeptide
Sponsor
Academic research programs (Imperial College, others)
Stage
Phase 1/2 across indications
Lead use cases
Fertility induction, sexual response, mood research

What it is

Kisspeptin is a peptide product of the KISS1 gene that acts on the GPR54 receptor on hypothalamic neurons to drive gonadotropin-releasing hormone (GnRH) release — placing it at the top of the reproductive endocrine cascade. KP-54 is the most-studied 54-amino-acid form; shorter active fragments (KP-10, KP-13) are also being investigated.

Current research status

Multiple Phase 1 and Phase 2 academic programs are exploring kisspeptin in fertility induction (as an alternative to hCG trigger in IVF), in hypoactive sexual desire-related contexts, and in PCOS. Phase 3 development for any specific indication has not yet advanced.

Mechanistic rationale

Kisspeptin signaling through GPR54 activates hypothalamic GnRH neurons. The downstream cascade — GnRH → LH/FSH → gonadal steroids — produces effects on reproductive function, but kisspeptin neurons also project to brain regions involved in emotional and sexual response, suggesting effects beyond classical reproductive endocrinology.

Available evidence

Fertility / IVF trigger — Kisspeptin has been tested as an alternative to hCG for inducing oocyte maturation in IVF cycles, with reduced ovarian hyperstimulation syndrome risk reported in early trials.[1]

Sexual response — Imperial College trials in men with hypoactive sexual desire and in women have shown effects on brain activity in regions associated with sexual response.[2]

PCOS — Early-phase work exploring kisspeptin's role in restoring more physiologic LH pulse patterns.

Why it's interesting

Kisspeptin sits at a unique upstream position in the reproductive endocrine axis — by activating endogenous GnRH release rather than directly stimulating gonadal tissue, the downstream effects retain more physiologic regulation than direct hCG or FSH/LH administration. The IVF application specifically could meaningfully reduce ovarian hyperstimulation risk. The sexual-response and mood literature is at an earlier stage but mechanistically interesting.

Limitations & risks

Therapeutic-grade development has been slower than the underlying biology might suggest. Native kisspeptin has a short plasma half-life requiring infusion or short-acting administration formats; long-acting analogs are in development but not yet at the level of the major GLP-1 engineering programs. The breadth of potential indications (fertility, sexual function, mood, PCOS) has scattered development resources.

Community discussion notes

Discussed in fertility-treatment specialty contexts more than biohacker communities. Some discussion in sexual-wellness and mood-related contexts, often alongside PT-141 and oxytocin given partially overlapping use cases.

The takeaway

Kisspeptin represents one of the more interesting endogenous peptide stories in modern endocrinology — an upstream regulator with multiple potential clinical applications. The translation from the strong basic-science foundation to specific clinical therapeutics has been slower than the biology suggested it would be, but the IVF and sexual-response programs are the closest to generating clinical-evidence-grade data.

References

  1. Abbara A, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in IVF. J Clin Endocrinol Metab. 2015;100(9):3322-3331. https://pubmed.ncbi.nlm.nih.gov/26192876/
  2. Comninos AN, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. https://pubmed.ncbi.nlm.nih.gov/28112678/